{"id":15072,"date":"2023-08-17T21:58:00","date_gmt":"2023-08-17T13:58:00","guid":{"rendered":"https:\/\/flcube.com\/?p=15072"},"modified":"2024-11-26T22:09:04","modified_gmt":"2024-11-26T14:09:04","slug":"jd-healthcare-reports-34-revenue-growth-and-triples-non-ifrs-profits-in-2023-interim-report","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=15072","title":{"rendered":"JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report"},"content":{"rendered":"\n<p>JD Healthcare, a subsidiary of China&#8217;s e-commerce giant JD.com (<a href=\"https:\/\/www.google.com\/finance\/quote\/JD:NASDAQ\">NASDAQ: JD<\/a>), has released its 2023 interim financial report, showing a 34% year-on-year (YOY) increase in total revenues to RMB 27.11 billion (USD 3.72 billion). Non-IFRS net profits surged by 101.2% to RMB 2.44 billion (USD 334.7 million), indicating strong financial performance.<\/p>\n\n\n\n<p><strong>Sustained Demand for Online Consultations and User Growth<\/strong><br>During the period, JD Healthcare experienced ongoing demand for online consultations, with annual active users reaching nearly 169 million for the past 12 months, an increase of 37.3 million from the same period last year. The company&#8217;s internet hospital managed an average of over 440,000 online consultations per day, demonstrating the popularity of its digital health services.<\/p>\n\n\n\n<p><strong>Launch of Specialized Internet Medical Service Platforms<\/strong><br>In April and May, JD Healthcare launched the first batch of skin specialist internet medical service platforms and psychological service centers in China, respectively. These initiatives, staffed with thousands of medical experts, provide professional services in niche sectors, enhancing JD Healthcare&#8217;s offerings in specialized care.<\/p>\n\n\n\n<p><strong>Elderly Care Service and Pharmaceutical Supply Chain Expansion<\/strong><br>Furthermore, JD Healthcare introduced &#8220;elderly care throughout the year&#8221; services on JD Home Healthcare, its family doctor product. The company is also focusing on pharmaceutical supply chain omni-channel cooperation, with its online platform hosting over 36,000 third-party merchants, a 43.7% YOY increase. The omni-channel layout covers over 400 cities nationwide, with 1200 partner chain brands and 100,000 partner storefronts, 60% of which are in tier-three and below cities. JD Healthcare has also partnered with multiple world-leading drug and device companies, as well as wellness brands, to expand its reach and service offerings.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>JD Healthcare, a subsidiary of China&#8217;s e-commerce giant JD.com (NASDAQ: JD), has released its 2023&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,93],"tags":[88,27,1065,1064,1063,79],"class_list":["post-15072","post","type-post","status-publish","format-standard","hentry","category-company","category-digital","tag-e-commerce","tag-finanical-reports","tag-jd-healthcare","tag-jd-com","tag-nasdaq-jd","tag-online-hospitals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"JD Healthcare, a subsidiary of China&#039;s e-commerce giant JD.com (NASDAQ: JD), has released its 2023 interim financial report, showing a 34% year-on-year (YOY) increase in total revenues to RMB 27.11 billion (USD 3.72 billion). Non-IFRS net profits surged by 101.2% to RMB 2.44 billion (USD 334.7 million), indicating strong financial performance.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=15072\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=15072\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-17T13:58:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-26T14:09:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15072#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15072\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report\",\"datePublished\":\"2023-08-17T13:58:00+00:00\",\"dateModified\":\"2024-11-26T14:09:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15072\"},\"wordCount\":271,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"E-commerce\",\"Finanical Reports\",\"JD Healthcare\",\"JD.com\",\"NASDAQ: JD\",\"Online hospitals\"],\"articleSection\":[\"Company\",\"Digital\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15072#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15072\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=15072\",\"name\":\"JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-08-17T13:58:00+00:00\",\"dateModified\":\"2024-11-26T14:09:04+00:00\",\"description\":\"JD Healthcare, a subsidiary of China's e-commerce giant JD.com (NASDAQ: JD), has released its 2023 interim financial report, showing a 34% year-on-year (YOY) increase in total revenues to RMB 27.11 billion (USD 3.72 billion). Non-IFRS net profits surged by 101.2% to RMB 2.44 billion (USD 334.7 million), indicating strong financial performance.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15072#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=15072\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=15072#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report - Insight, China&#039;s Pharmaceutical Industry","description":"JD Healthcare, a subsidiary of China's e-commerce giant JD.com (NASDAQ: JD), has released its 2023 interim financial report, showing a 34% year-on-year (YOY) increase in total revenues to RMB 27.11 billion (USD 3.72 billion). Non-IFRS net profits surged by 101.2% to RMB 2.44 billion (USD 334.7 million), indicating strong financial performance.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=15072","og_locale":"en_US","og_type":"article","og_title":"JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=15072","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-08-17T13:58:00+00:00","article_modified_time":"2024-11-26T14:09:04+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=15072#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=15072"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report","datePublished":"2023-08-17T13:58:00+00:00","dateModified":"2024-11-26T14:09:04+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=15072"},"wordCount":271,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["E-commerce","Finanical Reports","JD Healthcare","JD.com","NASDAQ: JD","Online hospitals"],"articleSection":["Company","Digital"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=15072#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=15072","url":"https:\/\/flcube.com\/?p=15072","name":"JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-08-17T13:58:00+00:00","dateModified":"2024-11-26T14:09:04+00:00","description":"JD Healthcare, a subsidiary of China's e-commerce giant JD.com (NASDAQ: JD), has released its 2023 interim financial report, showing a 34% year-on-year (YOY) increase in total revenues to RMB 27.11 billion (USD 3.72 billion). Non-IFRS net profits surged by 101.2% to RMB 2.44 billion (USD 334.7 million), indicating strong financial performance.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=15072#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=15072"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=15072#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15072","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15072"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15072\/revisions"}],"predecessor-version":[{"id":15075,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/15072\/revisions\/15075"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15072"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15072"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15072"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}